You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Boehringer Ingelheim
McKesson
Baxter
Johnson and Johnson

Last Updated: July 15, 2020

DrugPatentWatch Database Preview

ZYFLO CR Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Zyflo Cr patents expire, and what generic alternatives are available?

Zyflo Cr is a drug marketed by Chiesi and is included in one NDA.

The generic ingredient in ZYFLO CR is zileuton. There are eight drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the zileuton profile page.

US ANDA Litigation and Generic Entry Outlook for Zyflo Cr

A generic version of ZYFLO CR was approved as zileuton by RISING on March 17th, 2017.

  Start Trial

US Patents and Regulatory Information for ZYFLO CR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chiesi ZYFLO CR zileuton TABLET, EXTENDED RELEASE;ORAL 022052-001 May 30, 2007 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ZYFLO CR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Chiesi ZYFLO CR zileuton TABLET, EXTENDED RELEASE;ORAL 022052-001 May 30, 2007   Start Trial   Start Trial
Chiesi ZYFLO CR zileuton TABLET, EXTENDED RELEASE;ORAL 022052-001 May 30, 2007   Start Trial   Start Trial
Chiesi ZYFLO CR zileuton TABLET, EXTENDED RELEASE;ORAL 022052-001 May 30, 2007   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Boehringer Ingelheim
McKesson
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.